JULIE SMYSER: Open Payments
NPI 1619990181 · CHARLES CITY, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$301 in 12 payments from 8 companies in 2025. Trend: 2023 $191 · 2024 $482 · 2025 $301
Food & beverage: $301
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 1 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| ABBVIE INC. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Biogen, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: ARISTADA, TRINTELLIX, FANAPT, VRAYLAR, HETLIOZ, CAPLYTA, ZURZUVAE, REXULTI.
Industry payments across VA — which companies pay providers there.
